Jesús Vaquero1, Mercedes Zurita2, Miguel A Rico2, Celia Bonilla2, Concepción Aguayo2, Cecilia Fernández3, Noemí Tapiador4, Marta Sevilla4, Carlos Morejón4, Jesús Montilla4, Francisco Martínez5, Esperanza Marín5, Salvador Bustamante6, David Vázquez6, Joaquín Carballido6, Alicia Rodríguez2, Paula Martínez2, Coral García7, Mercedes Ovejero8, Marta V Fernández2. 1. Neurosurgery Service, University Hospital Puerta de Hierro-Majadahonda, Autonomous University, Madrid, Spain; Neuroscience Research Unit, University Hospital Puerta de Hierro-Majadahonda, Autonomous University, Madrid, Spain. Electronic address: jvaqueroc@telefonica.net. 2. Neuroscience Research Unit, University Hospital Puerta de Hierro-Majadahonda, Autonomous University, Madrid, Spain. 3. Neurosurgery Service, University Hospital Puerta de Hierro-Majadahonda, Autonomous University, Madrid, Spain. 4. Rehabilitation Service, University Hospital Puerta de Hierro-Majadahonda, Autonomous University, Madrid, Spain. 5. Clinical Neurophysiology Service, University Hospital Puerta de Hierro-Majadahonda, Autonomous University, Madrid, Spain. 6. Urology Service, University Hospital Puerta de Hierro-Majadahonda, Autonomous University, Madrid, Spain. 7. Neuroimmunology Unit, University Hospital Puerta de Hierro-Majadahonda, Autonomous University, Madrid, Spain. 8. Sermes CRO, Madrid, Spain.
Abstract
BACKGROUND AIMS: Cell therapy with mesenchymal stromal cells (MSCs) offers new hope for patients suffering from spinal cord injury (SCI). METHODS: Ten patients with established incomplete SCI received four subarachnoid administrations of 30 × 106 autologous bone marrow MSCs, supported in autologous plasma, at months 1, 4, 7 and 10 of the study, and were followed until the month 12. Urodynamic, neurophysiological and neuroimaging studies were performed at months 6 and 12, and compared with basal studies. RESULTS: Variable improvement was found in the patients of the series. All of them showed some degree of improvement in sensitivity and motor function. Sexual function improved in two of the eight male patients. Neuropathic pain was present in four patients before treatment; it disappeared in two of them and decreased in another. Clear improvement in bladder and bowel control were found in all patients suffering previous dysfunction. Before treatment, seven patients suffered spasms, and two improved. Before cell therapy, nine patients suffered variable degree of spasticity, and 3 of them showed clear decrease at the end of follow-up. At this time, nine patients showed infra-lesional electromyographic recordings suggesting active muscle reinnervation, and eight patients showed improvement in bladder compliance. After three administrations of MSCs, mean values of brain-derived neurotrophic factor, glial-derived neurotrophic factor, ciliary neurotrophic factor, and neurotrophin 3 and 4 showed slight increases compared with basal levels, but without statistically significant difference. CONCLUSIONS: Administration of repeated doses of MSCs by subarachnoid route is a well-tolerated procedure that is able to achieve progressive and significant improvement in the quality of life of patients suffering incomplete SCI.
BACKGROUND AIMS: Cell therapy with mesenchymal stromal cells (MSCs) offers new hope for patients suffering from spinal cord injury (SCI). METHODS: Ten patients with established incomplete SCI received four subarachnoid administrations of 30 × 106 autologous bone marrow MSCs, supported in autologous plasma, at months 1, 4, 7 and 10 of the study, and were followed until the month 12. Urodynamic, neurophysiological and neuroimaging studies were performed at months 6 and 12, and compared with basal studies. RESULTS: Variable improvement was found in the patients of the series. All of them showed some degree of improvement in sensitivity and motor function. Sexual function improved in two of the eight male patients. Neuropathic pain was present in four patients before treatment; it disappeared in two of them and decreased in another. Clear improvement in bladder and bowel control were found in all patients suffering previous dysfunction. Before treatment, seven patients suffered spasms, and two improved. Before cell therapy, nine patients suffered variable degree of spasticity, and 3 of them showed clear decrease at the end of follow-up. At this time, nine patients showed infra-lesional electromyographic recordings suggesting active muscle reinnervation, and eight patients showed improvement in bladder compliance. After three administrations of MSCs, mean values of brain-derived neurotrophic factor, glial-derived neurotrophic factor, ciliary neurotrophic factor, and neurotrophin 3 and 4 showed slight increases compared with basal levels, but without statistically significant difference. CONCLUSIONS: Administration of repeated doses of MSCs by subarachnoid route is a well-tolerated procedure that is able to achieve progressive and significant improvement in the quality of life of patients suffering incomplete SCI.
Authors: Emmanouil I Damianakis; Ioannis S Benetos; Dimitrios Stergios Evangelopoulos; Aikaterini Kotroni; John Vlamis; Spyridon G Pneumaticos Journal: Cureus Date: 2022-04-28
Authors: Eldon Loh; Magdalena Mirkowski; Alexandria Roa Agudelo; David J Allison; Brooke Benton; Thomas N Bryce; Sara Guilcher; Tara Jeji; Anna Kras-Dupuis; Denise Kreutzwiser; Oda Lanizi; Gary Lee-Tai-Fuy; James W Middleton; Dwight E Moulin; Colleen O'Connell; Steve Orenczuk; Patrick Potter; Christine Short; Robert Teasell; Andrea Townson; Eva Widerström-Noga; Dalton L Wolfe; Nancy Xia; Swati Mehta Journal: Spinal Cord Date: 2022-02-05 Impact factor: 2.473